{
    "title": "108_hr5306",
    "content": "The Act titled \"New War on Cancer Act\" provides nonpatent market exclusivity for cancer drugs under a new subchapter in the Federal Food, Drug, and Cosmetic Act. This includes recommendations for investigations of cancer drugs. The \"New War on Cancer Act\" allows sponsors of cancer drugs to request written recommendations from the Secretary for nonclinical and clinical investigations required before approval or licensing for use in cancer treatment. The \"New War on Cancer Act\" allows sponsors of cancer drugs to request written recommendations from the Secretary for approval or licensing under specific sections, with regulations to be established for implementation. \"SEC. 576. DESIGNATION OF CANCER DRUGS.\" The sponsor of a drug may request the Secretary to designate the drug as a cancer drug before submitting an application. The Secretary will designate the drug as a cancer drug if it is being investigated for use in cancer treatment. Before a drug is approved or licensed, the manufacturer or sponsor must notify the Secretary of any discontinuance of production or decision to discontinue pursuit of approval. Notice of drug designation will be made public. The Secretary will regulate procedures for drug designation under subsections (a) and (b), ensuring public availability of information. \"Market protection for cancer drugs under SEC. 577.\" Market protection for cancer drugs under SEC. 577 states that the Secretary may not approve another application or issue a license for a designated cancer drug until seven years after the initial approval. During a seven-year period after initial approval, the Secretary may approve another application or issue a license for a designated cancer drug if the current holder cannot assure sufficient quantities or provides written consent. During a seven-year period, the Secretary may approve other applications or issue licenses with the consent of the current holder before the expiration of the period. The Secretary may approve applications or issue licenses with the consent of the current holder before the expiration of the period for cancer drugs. The protocols for investigations of cancer drugs should include patients who need the drug for treatment and cannot be treated by available alternatives. Section 505(j)(5)(F)(ii) of the Federal Food, Drug, and Cosmetic Act is amended to extend the patent term for cancer drugs. Similarly, Section 156(c) of title 35, United States Code, is also amended to exclude paragraphs (2) and (3) for drugs approved for use in cancer treatment."
}